These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10853880)

  • 21. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
    Transon C; Leemann T; Vogt N; Dayer P
    Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.
    Dorado P; Cavaco I; Cáceres MC; Piedade R; Ribeiro V; Llerena A
    Eur J Clin Pharmacol; 2008 Oct; 64(10):967-70. PubMed ID: 18548238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
    Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
    Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
    Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
    Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.
    Dorado P; Berecz R; Norberto MJ; Yasar U; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 Jul; 59(3):221-5. PubMed ID: 12734606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling of aceclofenac metabolism to major metabolites in healthy volunteers.
    Kim E; Ihm C; Kang W
    Drug Metab Pharmacokinet; 2016 Dec; 31(6):458-463. PubMed ID: 27839691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of CYP2C9 polymorphism in losartan oxidation.
    Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
    Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
    Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers.
    Rajnarayana K; Venkatesham A; Krishna DR
    Drug Metabol Drug Interact; 2007; 22(2-3):165-74. PubMed ID: 17708066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.
    Zi J; Liu D; Ma P; Huang H; Zhu J; Wei D; Yang J; Chen C
    Drug Metab Pharmacokinet; 2010; 25(4):343-50. PubMed ID: 20814155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.
    Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
    Eur J Clin Pharmacol; 2003 Apr; 58(12):791-4. PubMed ID: 12698304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.